Wow, what an interesting trading day for shares of Omeros Corporation (NASDAQ:OMER). The stock began the day up slightly and bounced around quite a bit over the course of the trading day, dropping into the red for the first time at around 3:30 p.m. ET. Then with 12 minutes left in the trading day and still in the red, shares suddenly spiked from $13.50 to a high of $15.00 within a matter of minutes. While traders are speculating that news will be released sometime today or over the weekend, there is nothing official as of us publishing this story beside a few very general rumors. Whether news leaked or this was just an anxious buyer looking to get into Omeros Corporation’s (NASDAQ:OMER) stock before the end of the week, we have no clue. We will be watching for news and update this story should anything break over the weekend.
The stock increased 8.18% or $1.11 during the last trading session, hitting $14.68. About 2.56M shares traded hands or up 517.89% from the average. OMER has declined 35.01% since May 15, 2015 and is currently downtrending. It has underperformed the S&P500 by 32.75%.
From a total of 5 analysts covering Omeros (NASDAQ:OMER) stock, 5 rate it a “Buy”, 0 a “Sell”, and 0 a “Hold”. This means that 100% of the ratings are positive. The highest target price is $75 while the lowest target price is $30. The mean of all analyst targets is $49.20 which is 235.15% above today’s ($14.68) stock price. Omeros was the topic of 8 analyst reports since August 10, 2015 according to the firm StockzIntelligence Inc. Needham maintained shares on November 11 with a “Buy” rating. WBB Securities maintained OMER stock in a recent report from August 18 with a “Strong Buy” rating. Finally, TH Capital initiated the stock with a “Buy” rating in a report they issued on an August 10.
The institutional sentiment decreased to 1.41 in Q2 2015. It’s down 0.66, from 2.07 in 2015Q2. The ratio dropped, as 15 funds sold all their Omeros Corporation shares they owned while 24 reduced their positions. 11 funds bought stakes while 44 increased their total positions. Institutions now own 18.35 million shares which is 6.76% less than the previous share count of 19.68 million in 2015Q2.
Cormorant Asset Management Llc holds 3.43% of its total portfolio in Omeros Corporation, equating to 1.96 million shares. Rtw Investments Llc owns 482,831 shares representing 1.67% of their total US portfolio. Moreover, American Financial Group Inc has 0.55% of their total portfolio invested in the company, equating to 695,101 shares. The Idaho-based Caprock Group Inc. has a total of 0.51% of their portfolio invested in the stock. Stoneridge Investment Partners Llc, a Pennsylvania-based fund reported 309,279 shares owned.
Since March 26, 2015, the stock had 1 insider buy, and 1 insider sale for a total of $12,682 in net activity. Demopulos Peter A Md bought 3,962 shares worth $50,238. Cable Thomas J. sold 2,000 shares worth $37,556.
Omeros Corporation is a biopharmaceutical company. The company has a market cap of $515.25 million. The Firm is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. It currently has negative earnings. The Company’s marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens , which is replacement surgery, to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain.